Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Category: Drug delivery
Vaccines against COVID-19
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
Can Estrogen and Other Sex Hormones Help Men Survive Covid-19?
The gender gap in coronavirus survival became apparent early in the pandemic. Reports from China indicated men were dying at
CycloLab at BIO Digital
As the readers of Cyclodextrin News have been already informed, 2020 BIO International Convention will be a digital event to
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Amirian and Levy have recently collected the knowledge on remdesivir and its nucleoside analog [1]. This overview can be interesting
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Chlorpromazine complexation with Sugammadex – an extremely high complexation constant
An in press paper on detailed ITC and NMR study of chlorpromazin complexation with various cyclodextrins reports on an unexpected
Symposium of Drug Delivery Systems – 2020 (SDDS-2020) Postponed to 2021 (SDDS-2021)
The 9th Annual International Symposium of Drug Delivery Systems – 2020 (SDDS-2020) which will was originally planned during July 15-17,
2nd Pharmacology & Toxicology Conference
2nd Pharmacology & Toxicology Conference will be held on January 16, 2021 read more:at Sorbonne University in Paris. Some keynote
Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial
A recently published study from the National Institutes of Health reports on the efficacy of Gilead’s promising antiviral therapy remdesivir